Progression-free and overall survival in ovarian cancer patients treated with CVac, a mucin 1 dendritic cell therapy in a randomized phase 2 trial

BACKGROUND: CAN-003 was a randomized, open-label, Phase 2 trial evaluating the safety, efficacy and immune outcomes of CVac, a mucin 1 targeted-dendritic cell (DC) treatment as a maintenance therapy to patients with epithelial ovarian cancer (EOC). METHODS: Patients (n = 56) in first (CR1) or second...

Descripción completa

Detalles Bibliográficos
Autores principales: Gray, H. J., Benigno, B., Berek, J., Chang, J., Mason, J., Mileshkin, L., Mitchell, P., Moradi, M., Recio, F. O., Michener, C. M., Secord, A. Alvarez, Tchabo, N E., Chan, J. K., Young, J., Kohrt, H., Gargosky, S. E., Goh, J. C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4915201/
https://www.ncbi.nlm.nih.gov/pubmed/27330807
http://dx.doi.org/10.1186/s40425-016-0137-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4915201/
https://www.ncbi.nlm.nih.gov/pubmed/27330807
http://dx.doi.org/10.1186/s40425-016-0137-x

Ejemplares similares